News
Northern Ireland expands bowel cancer screening programme
Thousands more people in Northern Ireland will be invited for potentially life-saving bowel cancer screening after Health Minister Robbie Butler announced a major expansion of the regional screening programme. From November 2026, the Northern Ireland Bowel
Cancer Screening Programme will begin extending invitations to people aged 59, with 58-year-olds joining the programme from April 2027. The phased rollout will continue until everyone aged 50 to 74 is eligible by 2031. The expansion is designed to detect bowel cancer earlier, improving treatment outcomes and helping to save lives. Once fully implemented, the programme will invite an additional 135,000 people every year, increasing participation by around 80% compared with current screening levels. The phased rollout will ensure screening, diagnostic and treatment services can
manage the increased deman, while maintaining high standards of care. Health Minister, Robbie Butler, commented:
“Extending screening to people aged 50 to 59 will help identify more cancers at an earlier stage, when treatment is most effective. This investment will not only improve outcomes for patients but is also expected to deliver annual health service savings of between £1.7 million and £2 million once fully implemented.” The UK National Screening Committee has
recommended that bowel cancer screening should be offered to individuals aged 50 to 74 years of age, every two years, using a faecal immunochemical test (FIT). Currently in Northern Ireland, bowel cancer
screening is offered to individuals aged between 60 and 74 years old, every two years, using FIT. All bowel screening samples are processed and examined at a Laboratory based in the Northern Health and Social Care Trust.
Data collected from this important extension
in the screening programme will also be used to inform future reductions to the threshold for the screening test (this is known as the screening FIT threshold). At present, the Northern Ireland Bowel Cancer Screening Programme uses a FIT threshold of 120 micrograms of blood per gram of faeces. By lowering the screening test threshold, the screening programme will in the future have the potential to detect even more abnormal growths that can develop into cancer and also to detect more cancers.
UK first: testicular tissue transplanted to help restore fertility
Doctors in Edinburgh have performed a pioneering procedure to transplant a young man’s testicular tissue that was frozen before he underwent chemotherapy, in a potential breakthrough for male fertility preservation. The trial procedure, carried out by NHS
Lothian and underpinned by a decade’s worth of research from the University of Edinburgh, is the first of its kind in the UK and only the second reported worldwide. The 19-year-old student had testicular tissue removed and frozen in 2023 before undergoing a bone marrow transplant to treat a serious blood disorder. The treatment, which involves high dose chemotherapy, can permanently damage the cells needed to produce sperm, leaving children who undergo it at risk of infertility in adulthood. Three years after his treatment, tests showed that the patient had no sperm in his semen. In August 2026, doctors transplanted some of his previously frozen testicular tissue back into his body in the hope that it will begin to produce sperm. He has recovered well following the procedure and will now be closely monitored. After eight months, some of the transplanted tissue will be removed and examined to determine whether sperm have been produced. The procedure could eventually offer a
way for boys who have had testicular tissue preserved before undergoing sterilising cancer treatment to have children.
Trial to test endometriosis pain management programme The new 5-year project will look at whether a
A new £2.4 million study funded by the NIHR will test whether an innovative pain management programme can improve life for women living with endometriosis. The UK-wide trial is being led by researchers at the University of Aberdeen. It will evaluate a tailored plan designed to help women whose pain continues despite previous surgery or medication. Endometriosis is a common condition that affects 1 in 10 women. It causes persistent pelvic pain, chronic fatigue, and can disrupt all aspects of daily life, work and relationships. It can also impact plans to have children. There is currently no cure. Standard options like surgery and hormonal therapies often provide only temporary relief. Pain returns in up to half of cases within 5 years of surgery, leaving many women with few long-term options.
12
www.clinicalservicesjournal.com I November 2026
remotely delivered, endometriosis-specific Pain Management Programme (e-PMP) can offer a more lasting solution for women whose pain is inadequately controlled by surgery or medication. l The 12-week e-PMP course includes: l Psychotherapy informed by Cognitive Behavioural Therapy (CBT)
l Specialist physiotherapy l Advice on relationships, intimacy, and communication
l Guidance on self-compassion l Support to optimise medication and lower side effects
Women taking part will be recruited by their specialists. The trial will compare premenopausal women who receive the new programme alongside
standard care against those receiving standard care alone. It is open to women who continue to experience chronic pelvic pain despite previous treatment. Alongside health outcomes, the team will assess cost-effectiveness. The findings could help shape future NHS resource allocation and clinical guidelines. Dr. Lucky Saraswat, Honorary Senior Lecturer at the University of Aberdeen and Consultant Gynaecologist, who is leading the study, said: “This study will help us understand whether a tailored, interdisciplinary pain management programme can offer meaningful, long-term improvements in quality of life.
“If effective, e-PMP could become a vital new
treatment option, particularly for women who wish to avoid repeated surgery or hormonal therapies, or who are planning a pregnancy.”
wedmoments.stock -
stock.adobe.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71